Compagnone Miriam, Bruno Antonio Giulio, Saia Francesco
U.O. Cardiologia, Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna.
G Ital Cardiol (Rome). 2020 Feb;21(2 Suppl 1):48S-51S. doi: 10.1714/3311.32821.
Percutaneous transcatheter left atrial appendage occlusion and transcatheter mitral valve repair with the MitraClip system represent new therapeutic strategies for selected patients at high risk for both hemorrhagic and cardioembolic events or with symptomatic heart failure and moderate-to-severe mitral valve regurgitation, respectively. We report the case of an 84-year-old patient with severe degenerative mitral regurgitation hospitalized for a first episode of atrial fibrillation, angina pectoris and heart failure. The patient presented a clinical history of spontaneous cerebral bleeding, severe three-vessel coronary disease and multiple comorbidities that contraindicated a conventional surgical treatment. After an accurate clinical-instrumental evaluation, the local Heart Team indicated a combined procedure of percutaneous left atrial appendage closure and transcatheter mitral valve repair with the MitraClip system, followed by multivessel percutaneous coronary intervention (PCI) with drug-eluting stent implantation. Dual antiplatelet treatment was prescribed for 12 months after PCI.
经皮经导管左心耳封堵术以及使用MitraClip系统进行经导管二尖瓣修复术,分别为选定的有出血和心脏栓塞事件高风险的患者,或有症状性心力衰竭和中重度二尖瓣反流的患者代表了新的治疗策略。我们报告了一名84岁患有严重退行性二尖瓣反流的患者,因首次发作房颤、心绞痛和心力衰竭住院。该患者有自发性脑出血、严重三支血管冠状动脉疾病和多种合并症的临床病史,这些情况均禁忌进行传统外科治疗。经过准确的临床器械评估后,当地心脏团队建议采用经皮左心耳封堵术和使用MitraClip系统进行经导管二尖瓣修复术的联合手术,随后进行多支血管经皮冠状动脉介入治疗(PCI)并植入药物洗脱支架。PCI术后给予12个月的双联抗血小板治疗。